These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 16461183

  • 21. Secondary aldosteronism.
    Corry DB, Tuck ML.
    Endocrinol Metab Clin North Am; 1995 Sep; 24(3):511-29. PubMed ID: 8575407
    [Abstract] [Full Text] [Related]

  • 22. Renin-angiotensin-aldosterone and hypertension.
    Kotchen TA, Guthrie GP.
    Endocr Rev; 1980 Sep; 1(1):78-99. PubMed ID: 6112143
    [No Abstract] [Full Text] [Related]

  • 23. [The renin-angiotensin-aldosterone (RAA) system in endocrine diseases].
    Zdrojewicz Z.
    Wiad Lek; 1990 Jul 01; 43(13):679-84. PubMed ID: 2256331
    [Abstract] [Full Text] [Related]

  • 24. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
    Duprez DA.
    J Hypertens; 2006 Jun 01; 24(6):983-91. PubMed ID: 16685192
    [Abstract] [Full Text] [Related]

  • 25. Role of the renin-angiotensin-aldosterone system in the regulation of blood pressure.
    Barger AC.
    Adv Nephrol Necker Hosp; 1980 Jun 01; 9():271-93. PubMed ID: 6250379
    [No Abstract] [Full Text] [Related]

  • 26. [Cardio-protection and cardio-reparation in systemic arterial hypertension].
    Vallés Belsué F, Anguita Sánchez M.
    Rev Esp Cardiol; 1997 Jun 01; 50 Suppl 4():49-52. PubMed ID: 9411587
    [Abstract] [Full Text] [Related]

  • 27. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.
    Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M.
    J Hypertens; 2007 Jan 01; 25(1):177-86. PubMed ID: 17143190
    [Abstract] [Full Text] [Related]

  • 28. Comparison of changes in cardiac structure after treatment in secondary hypertension.
    Yoshitomi Y, Nishikimi T, Abe H, Yoshiwara F, Suzuki T, Ashizawa A, Nagata S, Kuramochi M, Matsuoka H, Omae T.
    Hypertension; 1996 Mar 01; 27(3 Pt 1):319-23. PubMed ID: 8698432
    [Abstract] [Full Text] [Related]

  • 29. [Hypertensive syndrome in kidney diseases].
    Tareeva IE, Kutyrina IM.
    Klin Med (Mosk); 1985 Apr 01; 63(4):6-12. PubMed ID: 3897700
    [No Abstract] [Full Text] [Related]

  • 30. The renin-angiotensin system and aldosterone in hypertension: a brief review of some aspects.
    Fraser R, Brown JJ, Lever AF, Morton JJ, Robertson JI.
    Int J Obes; 1981 Apr 01; 5 suppl 1():115-23. PubMed ID: 7016779
    [Abstract] [Full Text] [Related]

  • 31. [Renal sequelae of sympathetic hyperactivity].
    Watschinger B, Habicht A.
    Wien Med Wochenschr; 2004 Apr 01; 154 Spec No 1(1):7-9. PubMed ID: 15346546
    [No Abstract] [Full Text] [Related]

  • 32. Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones.
    Sun Y, Weber KT.
    Ann Med; 1998 Aug 01; 30 Suppl 1():3-8. PubMed ID: 9800877
    [Abstract] [Full Text] [Related]

  • 33. Myocardial fibrosis: role of ventricular systolic pressure, arterial hypertension, and circulating hormones.
    Weber KT, Brilla CG, Janicki JS, Reddy HK, Campbell SE.
    Basic Res Cardiol; 1991 Aug 01; 86 Suppl 3():25-31. PubMed ID: 1781767
    [Abstract] [Full Text] [Related]

  • 34. Aldosteronism and hypertension.
    Calhoun DA.
    Clin J Am Soc Nephrol; 2006 Sep 01; 1(5):1039-45. PubMed ID: 17699324
    [Abstract] [Full Text] [Related]

  • 35. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
    Tsutamoto T, Tanaka T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T, Horie M.
    Hypertens Res; 2009 Aug 01; 32(8):670-4. PubMed ID: 19498438
    [Abstract] [Full Text] [Related]

  • 36. [Renin-angiotensin-aldosterone system: the present status and problems].
    Khristov V.
    Vutr Boles; 1979 Aug 01; 18(6):8-15. PubMed ID: 392945
    [No Abstract] [Full Text] [Related]

  • 37. [Renin-angiotensin-aldosterone system in water-electrolyte homeostasis].
    Anghel S.
    Med Interna (Bucur); 1972 May 01; 24(5):521-8. PubMed ID: 4340438
    [No Abstract] [Full Text] [Related]

  • 38. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B, Devereux RB, Kjeldsen SE, Lyle PA, Zhang Z, Edelman JM.
    Blood Press; 2007 May 01; 16(1):6-12. PubMed ID: 17453746
    [Abstract] [Full Text] [Related]

  • 39. Aldosterone: a risk factor for vascular disease.
    Fritsch Neves M, Schiffrin EL.
    Curr Hypertens Rep; 2003 Feb 01; 5(1):59-65. PubMed ID: 12530937
    [Abstract] [Full Text] [Related]

  • 40. The Franz Gross Memorial Lecture. The renin-aldosterone connection: past, present and future.
    Robertson JI.
    J Hypertens Suppl; 1984 Dec 01; 2(3):S1-14. PubMed ID: 6400362
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.